

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM796114

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	First Lien Security Agreement		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
BioClinica, Inc.		03/20/2023	Corporation: DELAWARE
Clinverse, Inc.		03/20/2023	Corporation: DELAWARE
MDDX LLC		03/20/2023	Limited Liability Company: CALIFORNIA
RECEIVING PARTY DATA			
Name:	Goldman Sachs Bank USA, as Collateral Agent		
Street Address:	200 West Street		
City:	New York		
State/Country:	NEW YORK		
Postal Code:	10282		
Entity Type:	Bank: UNITED STATES		
PROPERTY NUMBERS Total: 9			
Property Type	Number	Word Mark	
Registration Number:	4301652	CLINDEBIT	
Registration Number:	4298440	CLINNOTIFY	
Registration Number:	4261644	CLINPAY	
Registration Number:	4261721	CLINVERSE	
Registration Number:	4682861	CLINVIZ	
Registration Number:	3819389	BIOCLINICA	
Registration Number:	1912827	BONA FIDE	
Registration Number:	6085635	WEBHEART	
Registration Number:	5404871	IMAGE LEARN	
CORRESPONDENCE DATA			
Fax Number:	8009144240		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	800-713-0755		
Email:	Michael.Violet@wolterskluwer.com		
Correspondent Name:	CT Corporation		
Address Line 1:	4400 Easton Commons Way		

OP \$240.00 4301652

Address Line 2: Suite 125
Address Line 4: Columbus, OHIO 43219

NAME OF SUBMITTER:	Doris Ka
SIGNATURE:	/Doris Ka/
DATE SIGNED:	03/21/2023

Total Attachments: 11

source=eRT - BioClinica et al.GS Trademark Security Agreement 1L#page1.tif
source=eRT - BioClinica et al.GS Trademark Security Agreement 1L#page2.tif
source=eRT - BioClinica et al.GS Trademark Security Agreement 1L#page3.tif
source=eRT - BioClinica et al.GS Trademark Security Agreement 1L#page4.tif
source=eRT - BioClinica et al.GS Trademark Security Agreement 1L#page5.tif
source=eRT - BioClinica et al.GS Trademark Security Agreement 1L#page6.tif
source=eRT - BioClinica et al.GS Trademark Security Agreement 1L#page7.tif
source=eRT - BioClinica et al.GS Trademark Security Agreement 1L#page8.tif
source=eRT - BioClinica et al.GS Trademark Security Agreement 1L#page9.tif
source=eRT - BioClinica et al.GS Trademark Security Agreement 1L#page10.tif
source=eRT - BioClinica et al.GS Trademark Security Agreement 1L#page11.tif

RECORDATION FORM COVER SHEET TRADEMARKS ONLY

To the Director of the U. S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

1. Name of conveying party(ies):

- 1. BioClinica, Inc.
Corporation - Delaware, USA
 - 2. Clinverse, Inc.
Corporation - Delaware, USA
 - 3. MDDX LLC
Limited Liability Company - California, USA
- Partnership Limited Partnership
- Corporation- State: _____
- Other _____

Citizenship (see guidelines) _____

Additional names of conveying parties attached? Yes No

3. Nature of conveyance/Execution Date(s) :

Execution Date(s) March 20, 2023

- Assignment Merger
- Security Agreement Change of Name
- Other First Lien Security Agreement

2. Name and address of receiving party(ies)

Additional names, addresses, or citizenship attached? Yes No

Name: Goldman Sachs Bank USA, as Collateral Agent

Street Address: 200 West Street

City: New York

State: NY

Country: USA Zip: 10282

- Individual(s) Citizenship _____
- Association Citizenship _____
- Partnership Citizenship _____
- Limited Partnership Citizenship _____
- Corporation Citizenship _____
- Other Bank Citizenship USA

If assignee is not domiciled in the United States, a domestic representative designation is attached: Yes No
(Designations must be a separate document from assignment)

4. Application number(s) or registration number(s) and identification or description of the Trademark.

A. Trademark Application No.(s) Text

B. Trademark Registration No.(s)

see attached Schedule B

Additional sheet(s) attached? Yes No

C. Identification or Description of Trademark(s) (and Filing Date if Application or Registration Number is unknown):

5. Name & address of party to whom correspondence concerning document should be mailed:

Name: Doris Ka - Senior Paralegal (Intellectual Property)

Internal Address: Cahill Gordon & Reindel LLP

Street Address: 32 Old Slip

City: New York

State: NY Zip: 10005

Phone Number: (212) 701-3569

Docket Number: eRT 30860.0861 (1L)

Email Address: dka@cahill.com

6. Total number of applications and registrations involved:

9

7. Total fee (37 CFR 2.6(b)(6) & 3.41) \$ _____

- Authorized to be charged to deposit account
- Enclosed

8. Payment Information:

Deposit Account Number _____

Authorized User Name _____

9. Signature:

Doris Ka

Signature

March 21, 2023

Date

Doris Ka

Name of Person Signing

Total number of pages including cover sheet, attachments, and document:

11

Documents to be recorded (including cover sheet) should be faxed to (571) 273-0140, or mailed to: Mail Stop Assignment Recordation Branch, Director of the USPTO, P.O. Box 1450, Alexandria, VA 22313-1450

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This INTELLECTUAL PROPERTY SECURITY AGREEMENT (as amended, amended and restated, supplemented or otherwise modified from time to time, the “IP Security Agreement”) dated March 20, 2023, is among the Persons listed on the signature pages hereof (collectively, the “Grantors”) and GOLDMAN SACHS BANK USA, as Collateral Agent (in such capacity, together with any successor collateral agent, the “Collateral Agent”) for the Secured Parties (as defined in the First Lien Credit Agreement referred to below).

WHEREAS, ERESEARCHTECHNOLOGY, INC., a Delaware corporation (the “Parent Borrower”) has entered into the First Lien Credit Agreement, dated as of February 4, 2020 (as amended, amended and restated, supplemented or otherwise modified from time to time, the “First Lien Credit Agreement”), together with each lender from time to time party thereto (collectively, the “Lenders” and individually, a “Lender”), and GOLDMAN SACHS BANK USA, as administrative agent (in such capacity, together with any successor administrative agent, the “Administrative Agent”) and Collateral Agent and the other agents and parties from time to time party thereto. Terms defined in the First Lien Credit Agreement or in the Security Agreement (as defined below) and not otherwise defined herein are used herein as defined in the First Lien Credit Agreement or the Security Agreement, as the case may be (and in the event of a conflict, the applicable definition shall be the one given to such term in the Security Agreement).

WHEREAS, as a condition precedent to the making of the Loans by the Lenders from time to time, the issuance of Letters of Credit by the L/C Issuers from time to time, the entry by the Hedge Banks into Secured Hedge Agreements from time to time and the entry by the Cash Management Banks into Secured Cash Management Agreements from time to time, each Grantor has executed and delivered that certain First Lien Security Agreement, dated February 4, 2020, among the Grantors and the Collateral Agent (as amended, amended and restated, supplemented or otherwise modified from time to time, the “Security Agreement”).

WHEREAS, under the terms of the Security Agreement, the Grantors have granted to the Collateral Agent, for the benefit of the Secured Parties, a security interest in, among other property, certain intellectual property of the Grantors, and have agreed thereunder to execute this IP Security Agreement for recording with the U.S. Patent and Trademark Office and the United States Copyright Office.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each Grantor agrees as follows:

SECTION 1. Grant of Security. As security for the payment or performance, as the case may be, in full of all of the Obligations when due, the undersigned hereby unconditionally grants and pledges to the Collateral Agent and, its successors and permitted assigns, for the benefit of the Secured Parties, a continuing security interest in, and liens on, the undersigned right, title and interest in and to the Collateral, other than Excluded Property, in each case, as to each type of property described below, whether now owned or hereafter acquired by the undersigned, wherever located, and whether now or hereafter existing or arising (the “Collateral”):

(i) all patents, patent applications, utility models, statutory invention registrations and all inventions claimed or disclosed therein and all improvements thereto set forth in Schedule A hereto (the “Patents”);

(ii) all trademarks, trademark applications, service marks, domain names, trade dress, logos, designs, slogans, trade names, business names, corporate names and other source identifiers, whether registered or unregistered set forth in Schedule B hereto (provided that no security interest shall be granted in any United States “intent-to-use” application for registration of a trademark filed pursuant to Section 1(b) of the Lanham Act, to the extent that, and solely during the period, if any,

in which, the grant of a security interest therein would impair the validity or enforceability, or result in the voiding, of such intent-to-use application (or any registration that may issue therefrom) under applicable law, rule or regulation), together, in each case, with the goodwill symbolized thereby (the "Trademarks");

(iii) all copyrights, together with any moral rights, including, without limitation, copyrights in Computer Software (as defined in the Security Agreement), internet web site content, whether registered or unregistered, and exclusive licenses of registered copyrights, in each case, as set forth in Schedule C hereto (the "Copyrights");

(iv) all reissues, divisionals, continuations, continuations-in-part, extensions, renewals and reexaminations of any of the foregoing, all rights in the foregoing provided by international treaties or conventions, all rights corresponding thereto throughout the world and all other rights of any kind whatsoever of such Grantor accruing thereunder or pertaining thereto;

(v) any and all claims for damages and injunctive relief for past, present and future infringement, dilution, misappropriation, violation, misuse or breach with respect to any of the foregoing, with the right, but not the obligation, to sue for and collect, or otherwise recover, such damages; and

(vi) any and all proceeds of, collateral for, income, royalties and other payments now or hereafter due and payable with respect to, and supporting obligations relating to, any and all of the Collateral of or arising from any of the foregoing;

provided that notwithstanding anything to the contrary contained in the foregoing clauses (i) through (vi), the security interest created hereby shall not extend to, and the term "Collateral" shall not include, any Excluded Property.

SECTION 2. Security for Obligations. The grant of a security interest in, the Collateral by each Grantor under this IP Security Agreement secures the payment of all Obligations of such Grantor now or hereafter existing under or in respect of the Secured Documents (as such Secured Documents may be amended, amended and restated, supplemented, replaced, refinanced or otherwise modified from time to time (including any increases of the principal amount outstanding thereunder)), whether direct or indirect, absolute or contingent, and whether for principal, reimbursement obligations, interest, premiums, penalties, fees, indemnifications, contract causes of action, costs, expenses or otherwise. Without limiting the generality of the foregoing, this IP Security Agreement secures, as to each Grantor, the payment of all amounts that constitute part of the Obligations that would be owed by such Grantor to any Secured Party under the Secured Documents but for the fact that they are unenforceable or not allowable due to the existence of a bankruptcy, or reorganization or similar proceeding involving a Loan Party.

SECTION 3. Recordation. Each Grantor authorizes and requests that the Register of Copyrights, the Commissioner for Patents and the Commissioner for Trademarks record this IP Security Agreement.

SECTION 4. Execution in Counterparts. This IP Security Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.

SECTION 5. Grants, Rights and Remedies. This IP Security Agreement has been entered into in conjunction with the provisions of the Security Agreement. Each Grantor does hereby acknowledge and confirm that the grant of the security interest hereunder to, and the rights and remedies of, the Collateral Agent with respect to the Collateral are more fully set forth in the Security Agreement, the terms and provisions of which are incorporated herein by reference as if fully set forth herein. In the event of any

conflict between the terms of this IP Security Agreement and the terms of the Security Agreement, the terms of the Security Agreement shall govern.

SECTION 6. Governing Law; Jurisdiction; Etc.

(a) THIS IP SECURITY AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK WITHOUT GIVING EFFECT TO THE CONFLICTS OF LAWS PRINCIPLES THEREOF, BUT INCLUDING SECTION 5-1401 OF THE NEW YORK GENERAL OBLIGATIONS LAW.

(b) EACH PARTY HERETO IRREVOCABLY AND UNCONDITIONALLY SUBMITS, FOR ITSELF AND ITS PROPERTY, TO THE EXCLUSIVE JURISDICTION OF THE COURTS OF THE STATE OF NEW YORK SITTING IN NEW YORK CITY IN THE BOROUGH OF MANHATTAN AND OF THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK SITTING IN THE BOROUGH OF MANHATTAN, AND ANY APPELLATE COURT FROM ANY THEREOF, IN ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS IP SECURITY AGREEMENT, AND EACH OF THE PARTIES HERETO IRREVOCABLY AND UNCONDITIONALLY AGREES THAT ALL CLAIMS IN RESPECT OF ANY SUCH ACTION OR PROCEEDING MAY BE HEARD AND DETERMINED IN SUCH NEW YORK STATE COURT OR, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, IN SUCH FEDERAL COURT. EACH OF THE PARTIES HERETO AGREES THAT A FINAL JUDGMENT IN ANY SUCH ACTION OR PROCEEDING SHALL BE CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON THE JUDGMENT OR IN ANY OTHER MANNER PROVIDED BY LAW. NOTHING IN THIS IP SECURITY AGREEMENT SHALL AFFECT ANY RIGHT THAT THE ADMINISTRATIVE AGENT, COLLATERAL AGENT, ANY LENDER OR ANY L/C ISSUER MAY OTHERWISE HAVE TO BRING ANY ACTION OR PROCEEDING RELATING TO THIS IP SECURITY AGREEMENT AGAINST THE PARENT BORROWER OR ANY OTHER LOAN PARTY OR ITS PROPERTIES IN THE COURTS OF ANY JURISDICTION.

(c) EACH PARTY HERETO IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY OBJECTION THAT IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS IP SECURITY AGREEMENT IN ANY COURT REFERRED TO IN PARAGRAPH (b) OF THIS SECTION. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, THE DEFENSE OF AN INCONVENIENT FORUM TO THE MAINTENANCE OF SUCH ACTION OR PROCEEDING IN ANY SUCH COURT.

(d) EACH PARTY HERETO IRREVOCABLY CONSENTS TO SERVICE OF PROCESS IN THE MANNER PROVIDED FOR NOTICES IN SECTION 10.02 OF THE FIRST LIEN CREDIT AGREEMENT. NOTHING IN THIS IP SECURITY AGREEMENT WILL AFFECT THE RIGHT OF ANY PARTY HERETO TO SERVE PROCESS IN ANY OTHER MANNER PERMITTED BY APPLICABLE LAW.

(e) EACH PARTY TO THIS IP SECURITY AGREEMENT HEREBY EXPRESSLY WAIVES ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND, ACTION OR CAUSE OF ACTION ARISING UNDER THIS IP SECURITY AGREEMENT OR IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES HERETO OR ANY OF THEM WITH RESPECT TO THIS IP SECURITY AGREEMENT, OR THE TRANSACTIONS RELATED THERETO, IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER FOUNDED IN CONTRACT OR TORT OR OTHERWISE; AND EACH PARTY HEREBY AGREES AND CONSENTS THAT ANY SUCH CLAIM, DEMAND, ACTION OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY, AND THAT ANY PARTY

TO THIS AGREEMENT MAY FILE AN ORIGINAL COUNTERPART OR A COPY OF THIS SECTION 6(e) WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE SIGNATORIES HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY.


SECTION 7. Intercreditor Agreement. Notwithstanding anything herein to the contrary, the liens and security interests granted to the Collateral Agent pursuant to this IP Security Agreement in any Collateral and the exercise of any right or remedy by the Collateral Agent with respect to any Collateral hereunder are subject to the provisions of the Intercreditor Agreement, dated as of February 4, 2020 (as amended, restated, supplemented or otherwise modified from time to time, the "Intercreditor Agreement"), among Explorer Holdings, Inc., a Delaware corporation (referred to herein as "Holdings"), eResearchTechnology, Inc., a Delaware Corporation, (referred to herein as the "Parent Borrower"), the other Grantors from time to time party thereto, Goldman Sachs Bank USA, as First Lien Administrative Agent and Original First Lien Security Agent, Goldman Sachs Bank USA, as Second Lien Administrative Agent and Original Second Lien Security Agent and certain other Persons party or that may become party thereto from time to time. In the event of any conflict between the terms of the Intercreditor Agreement and this Agreement, the terms of the Intercreditor Agreement shall govern and control.

IN WITNESS WHEREOF, each Grantor and the Collateral Agent have caused this IP Security Agreement to be duly executed and delivered by its officer thereunto duly authorized as of the date first written above.

BIOCLINICA, INC.
CLINVERSE, INC.

DocuSigned by:

Maureen Marchek

By:  _____
Name: ~~Maureen Marchek~~ Signer Name: Maureen Marchek
Title: ~~Spring Vice President and Treasurer~~ Signing Reason: I approve this document
4C8324706864490FB1E24504AA03E2F3

MDDX LLC

By: _____
Name: Daniel S. Braem
Title: Vice President, Tax

[Signature Page to Intellectual Property Security Agreement]

TRADEMARK
REEL: 008009 FRAME: 0324

IN WITNESS WHEREOF, each Grantor and the Collateral Agent have caused this IP Security Agreement to be duly executed and delivered by its officer thereunto duly authorized as of the date first written above.

**BIOCLINICA, INC.
CLINVERSE, INC.**

By: _____
Name: Maureen Marchek
Title: Senior Vice President and Treasurer


MDDX LLC

DocuSigned by:
Daniel Braem
By: _____
Name: Daniel S. Braem
Title: Vice President, Tax
Signer Name: Daniel Braem
Signing Reason: I approve this document
Signed: Feb 15, 2023 | 11:01 AM EST
2AC42A4729F64064AB16E9F33756DE20

[Signature Page to Intellectual Property Security Agreement]

**TRADEMARK
REEL: 008009 FRAME: 0325**

GOLDMAN SACHS BANK USA, as Collateral Agent

By: 
Name: Luke Qiu
Title: Authorized Signatory

SCHEDULE A

U.S. PATENTS

Patent Title	Jurisdiction	Patent No.	Issue Date	Owner	Status
OPTIMISED REGION OF INTEREST SELECTION	U.S.	8538102	9/17/2013	BioClinica, Inc.	Issued
BREAST TISSUE DENSITY MEASURE	U.S.	8315446	11/20/2012	BioClinica, Inc.	Issued
PATHOLOGY INDICATING MEASURE RELATED TO CARTILAGE STRUCTURE AND AUTOMATIC QUANTIFICATION THEREOF	U.S.	8300910	10/30/2012	BioClinica, Inc.	Issued
BREAST TISSUE DENSITY MEASURE	U.S.	8285019	10/9/2012	BioClinica, Inc.	Issued
CARTILAGE CURVATURE	U.S.	8280126	10/2/2012	BioClinica, Inc.	Issued
BREAST TISSUE DENSITY MEASURE	U.S.	8218850	7/10/2012	BioClinica, Inc.	Issued
VERTEBRAL FRACTURE QUANTIFICATION	U.S.	8126240	2/28/2012	BioClinica, Inc.	Issued
METHOD OF DERIVING A QUANTITATIVE MEASURE OF A DEGREE OF CALCIFICATION OF AN AORTA	U.S.	7844090	11/30/2010	BioClinica, Inc.	Issued
METHOD OF DERIVING A QUANTITATIVE MEASURE OF A DEGREE OF CALCIFICATION OF AN AORTA	U.S.	7561727	7/14/2009	BioClinica, Inc.	Issued
METHOD OF DERIVING A QUANTITATIVE MEASURE OF A DEGREE OF CALCIFICATION OF AN AORTA	U.S.	7463758	12/9/2008	BioClinica, Inc.	Issued

U.S. TRADEMARKS

Trademark	Jurisdiction	Reg. No. (App. No.)	Reg. Date (App. Date)	Owner	Status
CLINDEBIT	U.S.	4301652	3/12/2013	Clinverse, Inc.	Registered
CLINNOTIFY	U.S.	4298440	3/5/2013	Clinverse, Inc.	Registered
CLINPAY	U.S.	4261644	12/18/2012	Clinverse, Inc.	Registered
CLINVERSE	U.S.	4261721	12/18/2012	Clinverse, Inc.	Registered
CLINVIZ	U.S.	4682861	2/3/2015	Clinverse, Inc.	Registered
BIOCLINICA	U.S.	3819389	7/13/2010	Bioclinica, Inc.	Registered
BONA FIDE	U.S.	1912827	8/15/1995	Bioclinica, Inc.	Registered
WEBHEART	U.S.	6085635	6/23/2000	Bioclinica, Inc.	Registered
IMAGE LEARN	U.S.	5404871	2/20/2018	MDDX LLC	Registered

SCHEDULE C

U.S. COPYRIGHTS

Title	Registration No.	Registration Date	Owner
Bio/Image base (version 1.22)	TXu000690282	1995-03-14	BioClinica, Inc.
TranSenda clinical trial management system	TXu001576352	2007-08-30	BioClinica, Inc.
TranSenda business process manager	TXu001576355	2007-08-30	BioClinica, Inc.
TrxAm system: TranSenda international	TXu001060588	2002-10-30	BioClinica, Inc.